Contents
Issue 156 • July 2025
In association with
In Depth
Why can’t the US figure out weight loss drug prices?
Psychedelic drug developers redesign trials to avoid Lykos faux pas
Can pharma tariffs “Make America Manufacture Again”?
Policy changes and digital strategies guide oncology research
The European Market Access Lag: 2021–2024
Vutrisiran marks first silencer approved for ATTR-CM
ASCO 2025: Key highlights